CPT® Code 80351

1. Indications

The laboratory test associated with CPT® Code 80351 is indicated for the detection and measurement of synthetic cannabinoids in patients who may be experiencing symptoms related to their use. The following conditions or situations may warrant the performance of this test:

• Substance Use Evaluation Patients suspected of using synthetic cannabinoids may require testing to confirm the presence of these substances.
• Acute Toxicity Assessment Individuals presenting with symptoms of acute toxicity, such as agitation, anxiety, or hallucinations, may be tested to identify synthetic cannabinoid use.
• Monitoring Treatment Patients undergoing treatment for substance use disorders may be tested periodically to monitor for synthetic cannabinoid use.
• Legal or Employment Testing Testing may be required for legal reasons or as part of employment screening processes to ensure compliance with substance use policies.

2. Procedure

The procedure for testing synthetic cannabinoids as per CPT® Code 80351 involves several key steps, which are outlined below:

• Sample Collection The first step in the procedure is the collection of biological samples. A blood sample is obtained through a venipuncture, which is a method of drawing blood from a vein. For urine testing, a sample can be collected either through random voiding or catheterization, depending on the clinical scenario. Saliva samples are collected using a swab or in a sample cup, ensuring that the collection method is appropriate for the type of analysis being performed.
• Initial Screening Once the samples are collected, the urine sample undergoes an initial screening using enzyme-linked immunosorbent assay (ELISA). This screening method is designed to detect the presence of synthetic cannabinoids in the urine. If the initial screening yields a positive result, further confirmation testing is conducted.
• Confirmation Testing For urine samples that test positive, confirmation is performed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). This advanced testing method provides a more accurate and specific identification of the synthetic cannabinoids present in the sample. Blood and saliva samples are also analyzed using liquid chromatography-tandem mass spectrometry to ensure precise measurement of synthetic cannabinoids.

3. Post-Procedure

After the completion of the testing procedure, the results are analyzed and interpreted by qualified laboratory personnel. The findings are then reported to the requesting healthcare provider, who will use the information to guide clinical decision-making. Depending on the results, further evaluation or intervention may be necessary for the patient. It is important to consider that the detection of synthetic cannabinoids may have implications for treatment plans, legal matters, or employment status. Patients may be advised on the potential effects of synthetic cannabinoids and the importance of avoiding their use, especially in the context of mental health and safety.